412 related articles for article (PubMed ID: 26475993)
1. Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments.
Griggs JL; Sinnayah P; Mathai ML
Neurosci Biobehav Rev; 2015 Dec; 59():155-72. PubMed ID: 26475993
[TBL] [Abstract][Full Text] [Related]
2. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
Goldstone AP; Holland AJ; Butler JV; Whittington JE
Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
[TBL] [Abstract][Full Text] [Related]
3. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
[TBL] [Abstract][Full Text] [Related]
4. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of obesity in Prader-Willi syndrome.
Khan MJ; Gerasimidis K; Edwards CA; Shaikh MG
Pediatr Obes; 2018 Jan; 13(1):3-13. PubMed ID: 27863129
[TBL] [Abstract][Full Text] [Related]
6. Prader-Willi syndrome as a model of human hyperphagia.
Tauber M; Diene G; Mimoun E; Çabal-Berthoumieu S; Mantoulan C; Molinas C; Muscatelli F; Salles JP
Front Horm Res; 2014; 42():93-106. PubMed ID: 24732928
[TBL] [Abstract][Full Text] [Related]
7. Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.
Muscogiuri G; Formoso G; Pugliese G; Ruggeri RM; Scarano E; Colao A;
Rev Endocr Metab Disord; 2019 Jun; 20(2):239-250. PubMed ID: 31065942
[TBL] [Abstract][Full Text] [Related]
8. Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches.
Muscogiuri G; Barrea L; Faggiano F; Maiorino MI; Parrillo M; Pugliese G; Ruggeri RM; Scarano E; Savastano S; Colao A;
J Endocrinol Invest; 2021 Oct; 44(10):2057-2070. PubMed ID: 33891302
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome.
Correa-da-Silva F; Fliers E; Swaab DF; Yi CX
J Neuroendocrinol; 2021 Jul; 33(7):e12994. PubMed ID: 34156126
[TBL] [Abstract][Full Text] [Related]
10. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
De Waele K; Ishkanian SL; Bogarin R; Miranda CA; Ghatei MA; Bloom SR; Pacaud D; Chanoine JP
Eur J Endocrinol; 2008 Oct; 159(4):381-8. PubMed ID: 18603572
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive symptoms in Prader-Willi and "Prader-Willi-Like" patients.
State MW; Dykens EM; Rosner B; Martin A; King BH
J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):329-34. PubMed ID: 10087695
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of abnormal food-intake patterns in children with Prader-Willi syndrome and study of effects of naloxone.
Zipf WB; Berntson GG
Am J Clin Nutr; 1987 Aug; 46(2):277-81. PubMed ID: 3618531
[TBL] [Abstract][Full Text] [Related]
13. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings.
Angulo MA; Butler MG; Cataletto ME
J Endocrinol Invest; 2015 Dec; 38(12):1249-63. PubMed ID: 26062517
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.
Tan TM; Vanderpump M; Khoo B; Patterson M; Ghatei MA; Goldstone AP
J Clin Endocrinol Metab; 2004 Aug; 89(8):4162-5. PubMed ID: 15292365
[TBL] [Abstract][Full Text] [Related]
15. Development of the eating behaviour in Prader-Willi Syndrome: advances in our understanding.
McAllister CJ; Whittington JE; Holland AJ
Int J Obes (Lond); 2011 Feb; 35(2):188-97. PubMed ID: 20680019
[TBL] [Abstract][Full Text] [Related]
16. Calorie seeking, but not hedonic response, contributes to hyperphagia in a mouse model for Prader-Willi syndrome.
Davies JR; Humby T; Dwyer DM; Garfield AS; Furby H; Wilkinson LS; Wells T; Isles AR
Eur J Neurosci; 2015 Aug; 42(4):2105-13. PubMed ID: 26040449
[TBL] [Abstract][Full Text] [Related]
17. Caralluma fimbriata extract activity involves the 5-HT2c receptor in PWS Snord116 deletion mouse model.
Griggs JL; Mathai ML; Sinnayah P
Brain Behav; 2018 Dec; 8(12):e01102. PubMed ID: 30353709
[TBL] [Abstract][Full Text] [Related]
18. Advances in genetic mechanisms of hypothalamic dysfunction in Prader-Willi syndrome.
Wang XY; Sun R; Gao YQ
Yi Chuan; 2022 Oct; 44(10):899-912. PubMed ID: 36384726
[TBL] [Abstract][Full Text] [Related]
19. Obesity management in Prader-Willi syndrome: current perspectives.
Crinò A; Fintini D; Bocchini S; Grugni G
Diabetes Metab Syndr Obes; 2018; 11():579-593. PubMed ID: 30323638
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
